ACADIA Pharmaceuticals Inc (ACAD)

Etorro trading 970x250
ACADIA Pharmaceuticals Inc (ACAD) Logo

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130

ACADIA Pharmaceuticals Inc News and around…

Latest news about ACADIA Pharmaceuticals Inc (ACAD) common stock and company :

First Week of June 2022 Options Trading For Acadia Pharmaceuticals (ACAD)
02 Dec, 2021 FinancialContent

Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options begin trading this week, for the June 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 197 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
01 Dec, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatment.

Noteworthy ETF Inflows: LABU, ALXO, ABBV, ACAD
29 Nov, 2021 FinancialContent

Symbols mentioned in this story: LABU, ALXO, ABBV, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

10 Reddit Stocks that Flopped in 2021
26 Nov, 2021 Yahoo! Finance

In this article, we discuss the 10 Reddit stocks that flopped in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Reddit Stocks that Flopped in 2021. Retail investors have taken the stock market by storm this year, pouring hundreds of millions into equities and developing a […]

Notable ETF Inflow Detected - LABU, ALXO, ABBV, ACAD
19 Nov, 2021 FinancialContent

Symbols mentioned in this story: LABU, ALXO, ABBV, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
16 Nov, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the national launch of Yours, Truly, a multicultural, storytelling campaign to bring greater awareness and understanding of the varied experiences of the non-motor symptoms associated with Parkinson’s disease. In collaboration with StoryCorps, the campaign provides the Parkinson’s disease community a unique forum to record, share and archive their personal stories, in both Spanish and English, while also seeking to reduce the stigma around non-motor symptoms by sharing personal experiences. Available at YoursTrulyPDP.com, the website features stories from the Parkinson’s disease community, as well as access to bilingual educational resources from advocacy organizations from across the U.S.

December 31st Options Now Available For Acadia Pharmaceuticals
11 Nov, 2021 FinancialContent

Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options begin trading today, for the December 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new December 31st contracts and identified one put and one call contract of particular interest.

LABU, ALXO, ABBV, ACAD: Large Outflows Detected at ETF
11 Nov, 2021 FinancialContent

Symbols mentioned in this story: LABU, ALXO, ABBV, ACAD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

12 Health Care Stocks Moving In Tuesday's Intraday Session
09 Nov, 2021 FinancialContent

Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The ...

ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates
09 Nov, 2021 Yahoo! Finance

ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.

Acadia Pharmaceuticals Inc (ACAD) Q3 2021 Earnings Call Transcript
09 Nov, 2021 FinancialContent

ACAD earnings call for the period ending November 8, 2021.

ACADIA Pharmaceuticals: Q3 Earnings Insights
08 Nov, 2021 FinancialContent

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM. Here's what ...

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
08 Nov, 2021 Yahoo! Finance

Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
08 Nov, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
02 Nov, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX. The presentations demonstrate the suboptimal outcomes associated with the off-label use of currently available atypical antipsychotic treatments in managing dementia-related hallucinations and delusions, along with the related cost burdens.

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
01 Nov, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice President, Chief Insights and Analytics Officer, will continue to report to Steve Davis, Chief Executive Officer and continue to serve as a member of the company’s Executive Management Committee. He will assume responsibility for all sales and marketing functions, in addition to his current responsibilities leading commercial strategy, operations, patient services, and market access and reimbursement.

Where ACADIA Pharmaceuticals Stands With Analysts
01 Nov, 2021 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are ...

Humana (HUM) to Post Q3 Earnings: What's in the Cards?
29 Oct, 2021 Yahoo! Finance

Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.

ACAD December 10th Options Begin Trading
28 Oct, 2021 FinancialContent

Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new December 10th contracts and identified one put and one call contract of particular interest.

Notable Wednesday Option Activity: BYND, ALDX, ACAD
27 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Beyond Meat Inc (BYND), where a total of 64,304 contracts have traded so far, representing approximately 6.4 million underlying shares. That amounts to about 228.4% of BYND's average daily trading volume over the past month of 2.8 million shares..

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
27 Oct, 2021 Yahoo! Finance

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?
27 Oct, 2021 Yahoo! Finance

Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
27 Oct, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 8, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations.

Hedge Funds Are Souring On ACADIA Pharmaceuticals Inc. (ACAD)
25 Oct, 2021 Yahoo! Finance

With the second-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the third quarter of 2021. One of these stocks was ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) […]

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Con
25 Oct, 2021 FinancialContent

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held virtually and in-person November 9-12, 2021 in Boston, MA.

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
25 Oct, 2021 Yahoo! Finance

SAN DIEGO, October 25, 2021--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held virtually and in-person November 9-12, 2021 in Boston, MA.

15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
23 Oct, 2021 Yahoo! Finance

In this article, we will take a look at 15 biotech and pharmaceutical stocks to buy according to Palo Alto Investors. You can skip our detailed analysis of the fund’s history, investment strategy, and hedge fund performance, and go directly to the 5 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors. Palo […]

How The Parts Add Up: IYY Headed For $124
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.

Analysts are Cutting Price Targets of These 10 Stocks
15 Oct, 2021 Yahoo! Finance

In this article, we discuss the 10 stocks that analysts are cutting price targets of. If you want to skip our detailed analysis of these stocks, go directly to Analysts are Cutting Price Targets of These 5 Stocks. Two top economic experts have warned that there are signs that the United States economy is headed […]

ACADIA Pharmaceuticals Inc (ACAD) is a NASDAQ Common Stock listed in , ,

970x250